Cynapsus Therapeutics Inc. is a Canada-based clinical-stage, specialty pharmaceutical company. The Company is engaged in developing a sublingual thin filmstrip to manage OFF episodes associated with Parkinson’s disease. The Company’s drug candidate is APL–130277, which is a reformulation of apomorphine. The drug is an approved acute drug in the United States, Europe, Japan and other countries. The Company completed a CTH-105 Phase II clinical trial comprising approximately 16 people with Parkinson’s disease.
